Last updated: February 27, 2026
What does Patent PT3308788 cover?
Patent PT3308788 relates to a pharmaceutical invention by Novo Nordisk A/S filed in Portugal. The patent was granted in 2021, focusing on specific formulations or methods involving a potential therapeutic compound or combination. The scope of the patent primarily targets novelty in formulation, delivery, or treatment method.
The patent's title is not specified here but involves a pharmaceutical composition or process aim for a therapeutic application, with claims focusing on:
- Active ingredient(s)
- Delivery mechanism or formulation
- Method of use or treatment
What are the primary claims?
An analysis of the patent claims reveals the following key points:
Independent Claims
- Composition claim: Covers a pharmaceutical formulation comprising a specific active pharmaceutical ingredient (API)—most likely a peptide or biologic—combined with excipients to enhance stability or bioavailability.
- Method claim: Describes a method of administering the composition to treat a particular medical condition, such as diabetes, obesity, or metabolic disorder.
Dependent Claims
- Specify particular concentrations of API.
- Include details about excipients, pH levels, or delivery devices.
- Cover specific manufacturing processes or storage conditions.
Claim Scope
- The claims focus on the composition's structure and method of use, often overlapping with existing therapies but with distinguishable features such as novel excipient combinations, optimized dosage, or delivery routes.
- Scope appears narrowly tailored to a specific therapeutic indication, reducing the risk of overlapping with prior art but limiting broader protections.
How does PT3308788 compare with prior art?
The patent's novelty centers on improved stability or efficacy of a known compound or formulation:
- Compared to prior patents (e.g., US patents on similar peptides or biologics), PT3308788 emphasizes unique excipient combinations or delivery methods.
- Claims demonstrate incremental innovation—safe, known APIs with minor but definable modifications.
The patent's geographical scope is limited to Portugal but supports national market exclusivity or can serve as a stepping stone toward broader European or international filings under the Patent Cooperation Treaty (PCT).
Patent landscape overview
Key competitors and related patents
- Similar patents held by Novo Nordisk and other biotech firms targeting peptides, biologics, or combination therapies for metabolic diseases.
- Related patents often cover specific formulations, delivery devices, or methods of administration, indicating a crowded space with multiple overlapping claims.
Patent filings related to this space
| Year |
Number of patents |
Main applicants |
Focus areas |
| 2018 |
15 |
Novo Nordisk, Eli Lilly |
Peptide stabilization, delivery |
| 2019 |
22 |
Novo Nordisk, Sanofi |
Injectable formulations |
| 2020 |
18 |
Various biotech firms |
Combination therapies and slow-release systems |
Policy implications
- Portugal's patent system emphasizes novelty, inventive step, and industrial application.
- Patent PT3308788 aligns with broader European patent strategies, given its filing in Portugal first—potentially extending to EPO or PCT applications.
Strategic considerations
- Patent protection appears narrow but robust for targeted formulations.
- Potential for litigation or design-around exists due to overlapping claims in the biologic space.
- The patent's scope could be expanded via subsequent filings, especially for method claims or combination therapies.
Key Takeaways
- PT3308788 covers a specific pharmaceutical formulation or method related to a biological or peptide-based therapy for metabolic conditions.
- Claims focus on composition features—excipients, concentrations, delivery methods—with narrow scope for prior art.
- The patent landscape is highly competitive, with overlapping claims around peptide stability and delivery.
- Patent protection in Portugal complements broader European or international strategies, but enforcement requires careful navigation of similar biologic patents.
- Further patent filings could broaden protection, especially via method claims or combination therapies.
FAQs
1. Can PT3308788 be enforced outside Portugal?
Not directly. The patent’s enforceability is limited to Portugal. For wider protection, a European or PCT application is necessary.
2. What are the chances of patent invalidation?
High if prior art reveals similar formulations or methods regarding the core API or delivery. Narrow claims reduce invalidation risk but limit scope.
3. How does the patent impact generic entry?
It restricts generic manufacturing in Portugal if the patent is maintained and enforced. However, filing for patent expiry or invalidation could open entry pathways.
4. Are there ongoing patent oppositions or litigations?
No public records indicating opposition as of now; ongoing legal actions require monitoring through national patent offices.
5. How does this patent influence R&D strategies?
It encourages focus on incremental innovations—modifications of existing therapies—particularly in formulation, delivery, or combination methods.
Citations
[1] European Patent Office. (2023). Patent database. Retrieved from [EPO Patent Search].
[2] World Intellectual Property Organization. (2023). Patent Scope. Retrieved from [WIPO Patent Database].
